Chembio Diagnostics Inc (CEMI) was Reiterated by The Benchmark Company to “Speculative Buy” while Lowering the Price Target of the company shares to $ 9 from a previous price target of $10 . The Benchmark Company advised their investors in a research report released on Aug 11, 2016.
Chembio Diagnostics Inc closed down -0.04 points or -0.56% at $7.15 with 59,874 shares getting traded on Monday. Post opening the session at $7.14, the shares hit an intraday low of $7.0701 and an intraday high of $7.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jun 17, 2016, Sharon W Klugewicz (Chief Operating Officer) sold 3,000 shares at $8.40 per share price. According to the SEC, on Jun 2, 2016, Javan Esfandiari (Chief Science/Tech Officer) sold 25,000 shares at $8.57 per share price.
Chembio Diagnostics Inc. (Chembio) and its wholly owned subsidiary Chembio Diagnostic Systems Inc. develop manufacture market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s main products presently commercially available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples and are manufactured in a standard cassette format a dipstick format and a barrel format. Its Dual Path Platform (DPP) HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples as well as in all blood matrices. Additionally Chembio’s product pipeline includes a multiplex test that detects P24 HIV antigen as well as HIV 1/2 antibodies and a rapid test for the detection of Hepatitis-C antibodies.